MGC Pharmaceuticals to buy Australia’s top medicinal cannabis clinic
By Nikita Chaurasia  Date: 2020-07-20

MGC Pharmaceuticals to buy Australia’s top medicinal cannabis clinic

As reported by credible sources, MGC Pharmaceuticals Ltd, a European bio-pharma firm, aims to acquire the complete data, intellectual property, and operating clinic-based assets of Medicinal Cannabis Clinic Pty Ltd.

As per the agreement, the new company, which will be incorporated to hold all assets of MCC, will attain pertinent state and federal licenses. This permit will further enable the import and supply of medicinal cannabis products. The company would be able to offer inexpensive cannabinoid through the focused reduction of import, storage, and distribution costs per unit.

For those uninitiated, MGC Pharma specializes in production and development of medicines which are EU-GMP Phyto cannabinoid derived. It has signed an agreement with Cannvalate Pty Ltd in a bid to acquire its wholly owned subsidiary MCC, which s has an extensive network of patients and doctors.

Speaking of the move, co-founder & MD of MGC Pharma, said that the acquisition of MCC assets is a vital part of their strategy to expand their direct supply chain capabilities and distribution network in Australia, and world over. He further added that the organization will achieve its cashflow breakeven goals through this acquisition. The company looks forward to integrating high-quality clinics network of MCC, he said.

MGC Pharma has reportedly decided to continue services of MCC staff to maintain the continuity of operations of the new firm, ensuring exceptional clinical governance and independence. The fundamental business ethos, product offering, and existing operations of MCC will remain unchanged.

If reports are to be believed, the deal includes USD 400,000 in cash and USD 1 million in MGC Pharma shares. The clearance of the transaction is projected to be concluded within 90 days.

Source- https://www.proactiveinvestors.com.au/companies/news/924532/mgc-pharmaceuticals-moves-to-acquire-one-of-australia-s-leading-medicinal-cannabis-clinics-924532.html

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Borqs Technologies introduces BeSmartTrack™ for tracing COVID-19 virus
Borqs Technologies introduces BeSmartTrack™ for tracing COVID-19 virus
By Nikita Chaurasia

Lately, China-based leading developer of software application for IoT (Internet of Things) Borqs Technologies Inc. has gained significant attention upon launching its mobile smart tracking solution called BeSmartTrack™. The launch event reporte...

Fractyl raises series E funding of USD 55 million for diabetes cure
Fractyl raises series E funding of USD 55 million for diabetes cure
By Nikita Chaurasia

Fractyl Laboratories raised series E funding of USD 55 million to continue financing the pivotal clinical trial of its potential non-surgical, non-drug treatment for Type 2 diabetes. As per the trusted sources, the capital will be invested on mass-b...

Nokia Corp. partners with IISc to improve telecommunication solutions
Nokia Corp. partners with IISc to improve telecommunication solutions
By Nikita Chaurasia

Finnish multinational telecommunications giant Nokia Corporation has recently made it to the headlines after entering into a joint venture agreement with IISc (Indian Institute of Science) to launch the Nokia CoE (Centre of excellence) for Networked ...

Motorola acquires Pelco Inc. to expand its video security services
Motorola acquires Pelco Inc. to expand its video security services
By Nikita Chaurasia

Chicago-based telecommunication company, Motorola Solutions Inc., has made it to the headlines through its acquisition of Pelco Inc. from Transom Capital Group for $110 million dollars. For those uninitiated, Pelco Inc. is a security and surveillanc...

NeuroRx, Relief Therapeutics declare results of RLF-100 clinical trials
NeuroRx, Relief Therapeutics declare results of RLF-100 clinical trials
By Nikita Chaurasia

U.S.-based pharmaceutical company NeuroRx Inc., along with Relief Therapeutics Holding AG, a Swiss drug development company, have reportedly declared that aviptadil (RLF-100) clinical trials have showcased quick recuperation of respiratory failures a...